ArticleBMC cancer2026
Impact of mucinous histology on the efficacy of neoadjuvant immunotherapy in localized mismatch repair-deficient colorectal cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe response of mucinous colorectal cancer (CRC) to immunotherapy remains unclear. This study aimed to evaluate the efficacy of neoadjuvant immunotherapy in localized mucinous mismatch repair-deficient (dMMR) CRC.
methodsThis retrospective study included patients with localized dMMR CRC who underwent neoadjuvant immunotherapy. Patients were classified into adenocarcinoma (AC) and mucinous carcinoma (MC) groups. Clinicopathological and treatment data were recorded. Logistic regression analysis was performed to identify predictors of complete response (CR).
resultsA total of 220 patients were included, of whom 25(11.4%) had MC. Patients with MC had significantly lower clinical complete response (cCR) rates (20.0% vs. 44.1%, P = 0.021) and objective response rates (64.0% vs. 92.8%, P < 0.001) than those with AC. In addition, patients with MC showed lower pCR, poorer tumor regression, and more aggressive pathology. In MC patients, combination therapy was associated with greater tumor regression than anti-PD-1 monotherapy (83.3% vs. 28.6%, P = 0.045). Among patients who underwent surgery, the 2-year disease-free survival rate was 94.1% in the MC group and 100% in the AC group. Multivariate analysis identified MC histology as an independent negative predictor of CR (Odds ratio [OR] = 0.22, 95% confidence interval [CI]: 0.09-0.56; P = 0.002), whereas a treatment duration ≥ 3 months significantly increased the probability of CR in all patients. During neoadjuvant treatment, severe (grade 3-4) immune-related adverse events (irAEs) occurred in 15 patients (7.7%, 15/195) in the AC group and 1 patient (4.0%, 1/25) in the MC group.
conclusionPatients with localized MC dMMR CRC tend to have inferior responses to immunotherapy compared with patients with AC. Optimizing treatment duration or modifying treatment regimens may improve therapeutic outcomes in this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.